---
title: "Entera Bio prices USD 275 million private placement at USD 2.04 per share"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293933037.md"
description: "Entera Bio priced an oversubscribed USD 275 million private placement at USD 2.04 per share, led by BVF Partners. The transaction includes ordinary shares and pre-funded warrants, with closing expected around July 28, 2026. Proceeds will extend the cash runway into 2030 to fund Phase 3 studies for EB613. Upon closing, BVF gains rights to designate two board directors."
datetime: "2026-07-27T12:32:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293933037.md)
  - [en](https://longbridge.com/en/news/293933037.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293933037.md)
generator: "portal-rs"
---

# Entera Bio prices USD 275 million private placement at USD 2.04 per share

-   Entera Bio priced an oversubscribed private placement expected to raise USD 275 million in gross proceeds. \* Led by BVF Partners, with participation from several healthcare-focused investors; closing expected around July 28, 2026. \* Structure includes 122,961,215 ordinary shares at USD 2.04 each, with pre-funded warrants for up to 11,842,695 shares. \* Proceeds expected to extend cash runway into 2030, funding Phase 3 registrational studies for EB613 oral osteoporosis tablet. \* BVF to gain the right to designate two board directors upon closing, subject to standard eligibility requirements. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entera Bio Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270830PRIMZONEFULLFEED9798438) on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ENTX.US](https://longbridge.com/en/quote/ENTX.US.md)

## Related News & Research

- [Entera Bio says Phase 2 post-hoc analysis supports anabolic effect of oral EB613 in high-risk postmenopausal osteoporosis patients](https://longbridge.com/en/news/294825410.md)
- [Entera Bio Q2 FY26 net loss widens to $7.3 million; R&D expenses more than double to $3.2 million](https://longbridge.com/en/news/295272747.md)
- [Inhalation Sciences sets warrant exercise price at SEK 0.12 per share](https://longbridge.com/en/news/296936023.md)
- [Geox opens warrant exercise period at EUR 0.34 per share](https://longbridge.com/en/news/297074532.md)
- [Karman Line Acquisition says units begin trading separately into shares, warrants Aug. 27](https://longbridge.com/en/news/297045620.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**